+373.4%
AMD vs MRNA
+257.4%
+116.0%
-63.0%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 3y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | +7.3% | -0.9% | +8.2% | +7.4% |
| 7D | +13.1% | -3.8% | +16.9% | +13.4% |
| 30D | -7.0% | +16.4% | -23.3% | -7.6% |
| 3M | +16.6% | +310.6% | -294.0% | +4.0% |
| 6M | +20.5% | +370.3% | -349.8% | +2.8% |
| YTD | +158.2% | +743.3% | -585.1% | +95.0% |
| 1Y | +132.8% | +841.7% | -708.9% | +71.7% |
| All | +373.4% | +257.4% | +116.0% | +309.5% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 3y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
3y analysis · Full analysis span regression · 6 months rolling